Cidara Therapeutics, Inc. – NASDAQ:CDTX
Cidara Therapeutics stock price today
$61
+37.31
+157.49%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 22 minutes
Cidara Therapeutics stock price monthly change
+106.36%
month
Cidara Therapeutics stock price quarterly change
+106.36%
quarter
Cidara Therapeutics stock price yearly change
+2868.67%
year
Cidara Therapeutics key metrics
Market Cap | 165.31M |
Enterprise value | 51.01M |
P/E | -2.62 |
EV/Sales | 0.65 |
EV/EBITDA | -0.86 |
Price/Sales | 1.06 |
Price/Book | -28.38 |
PEG ratio | -0.05 |
EPS | -8.14 |
Revenue | 46.37M |
EBITDA | -38.11M |
Income | -36.46M |
Revenue Q/Q | -67.43% |
Revenue Y/Y | -44.23% |
Profit margin | -78.85% |
Oper. margin | -78.71% |
Gross margin | 0% |
EBIT margin | -78.71% |
EBITDA margin | -82.18% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCidara Therapeutics stock price history
Cidara Therapeutics stock forecast
Cidara Therapeutics financial statements
| Jun 2023 | 7.61M | -12.35M | -162.29% |
|---|---|---|---|
| Sep 2023 | 12.71M | -8.17M | -64.26% |
| Dec 2023 | 17.58M | -5.61M | -31.91% |
| Mar 2024 | 8.46M | -10.32M | -122.01% |
| 2025 | 42.85M | -39.42M | -92% |
|---|---|---|---|
| 2026 | 53.24M | -33.31M | -62.57% |
| 2027 | 138.05M | 47.12M | 34.13% |
| 2028 | 104.97M | 24.08M | 22.95% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 67986000 | 52.57M | 77.33% |
|---|---|---|---|
| Sep 2023 | 63468000 | 55.43M | 87.34% |
| Dec 2023 | 68530000 | 76.74M | 111.98% |
| Mar 2024 | 52716000 | 70.49M | 133.73% |
| Jun 2023 | 2.82M | -107K | -261K |
|---|---|---|---|
| Sep 2023 | -1.63M | -126K | 0 |
| Dec 2023 | -12.72M | -178K | 8K |
| Mar 2024 | -6.64M | -23K | -93K |
Cidara Therapeutics alternative data
| Sep 2023 | 73 |
|---|---|
| Oct 2023 | 73 |
| Nov 2023 | 73 |
| Dec 2023 | 73 |
| Jan 2024 | 73 |
| Feb 2024 | 73 |
| Mar 2024 | 73 |
| Apr 2024 | 73 |
| May 2024 | 69 |
| Jun 2024 | 69 |
| Jul 2024 | 69 |
Cidara Therapeutics other data
57.79%
-4.98%
of CDTX is owned by hedge funds
40
-11
30.31M
-780.92K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 81095 |
| Jun 2024 | 8000 | 0 |
| Sep 2024 | 0 | 1833 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SANDISON TAYLOR officer: Chief Me.. | Common Stock | 924 | $11.64 | $10,753 | ||
Sale | TARI LESLIE officer: CHIEF SCIENTIFIC OFFICER | Common Stock | 909 | $11.64 | $10,580 | ||
Purchase | STEIN JEFFREY director, officer.. | Common Stock | 8,000 | $13.21 | $105,680 | ||
Sale | TARI LESLIE officer: CHIEF SCIENTIFIC OFFICER | Common Stock | 21,029 | $0.67 | $14,089 | ||
Sale | SANDISON TAYLOR officer: Chief Me.. | Common Stock | 20,662 | $0.67 | $13,844 | ||
Sale | WARD SHANE officer: COO & CLO | Common Stock | 20,473 | $0.67 | $13,717 | ||
Sale | SHAH PREETAM officer: CFO & CBO | Common Stock | 18,931 | $0.67 | $12,684 | ||
Sale | TARI LESLIE officer: CHIEF SCIENTIFIC OFFICER | Common Stock | 18,469 | $0.95 | $17,509 | ||
Sale | SANDISON TAYLOR officer: Chief Me.. | Common Stock | 18,793 | $0.95 | $17,816 | ||
Purchase | TARI LESLIE officer: CHIEF SCIENTIFIC OFFICER | Common Stock | 10,000 | $0.97 | $9,700 |
| Patent |
|---|
Application Filling date: 21 Apr 2021 Issue date: 18 Aug 2022 |
Application Filling date: 18 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 25 Oct 2019 Issue date: 18 Nov 2021 |
Application Filling date: 5 Mar 2021 Issue date: 29 Jul 2021 |
Application Filling date: 5 Mar 2021 Issue date: 22 Jul 2021 |
Application Filling date: 14 Jun 2019 Issue date: 17 Jun 2021 |
Application Filling date: 2 Jul 2020 Issue date: 6 May 2021 |
Application Filling date: 29 Nov 2017 Issue date: 7 Jan 2021 |
Grant Filling date: 1 Aug 2019 Issue date: 22 Sep 2020 |
Application Filling date: 11 Jul 2018 Issue date: 27 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2017 11 Nov 2017 | Q3 2017 Earnings Call Transcript |
Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy
Cidara Therapeutics: All Stars Aligning In Favor Of CD388
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline
Buy Cidara Therapeutics For The Cloudbreak Platform
Cidara Therapeutics: Leveraging Antifungals To Move Into Cancer Therapy
Buy Cidara Therapeutics For Data Readout And European Foothold
Cidara Therapeutics: FDA Approval Dead Ahead
-
What's the price of Cidara Therapeutics stock today?
One share of Cidara Therapeutics stock can currently be purchased for approximately $61.
-
When is Cidara Therapeutics's next earnings date?
Unfortunately, Cidara Therapeutics's (CDTX) next earnings date is currently unknown.
-
Does Cidara Therapeutics pay dividends?
No, Cidara Therapeutics does not pay dividends.
-
How much money does Cidara Therapeutics make?
Cidara Therapeutics has a market capitalization of 165.31M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 0.6% to 63.91M US dollars.
-
What is Cidara Therapeutics's stock symbol?
Cidara Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CDTX".
-
What is Cidara Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cidara Therapeutics?
Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cidara Therapeutics's key executives?
Cidara Therapeutics's management team includes the following people:
- Dr. Jeffrey L. Stein Ph.D. Pres, Chief Executive Officer & Executive Director(age: 70, pay: $837,530)
- Dr. Taylor Sandison Chief Medical Officer(age: 53, pay: $593,850)
-
How many employees does Cidara Therapeutics have?
As Jul 2024, Cidara Therapeutics employs 69 workers, which is 5% less then previous quarter.
-
When Cidara Therapeutics went public?
Cidara Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 15 Apr 2015.
-
What is Cidara Therapeutics's official website?
The official website for Cidara Therapeutics is cidara.com.
-
Where are Cidara Therapeutics's headquarters?
Cidara Therapeutics is headquartered at 6310 Nancy Ridge Drive, San Diego, CA.
-
How can i contact Cidara Therapeutics?
Cidara Therapeutics's mailing address is 6310 Nancy Ridge Drive, San Diego, CA and company can be reached via phone at 858 752 6170.
Cidara Therapeutics company profile:
Cidara Therapeutics, Inc.
cidara.comExchange:
NASDAQ
Full time employees:
69
Industry:
Biotechnology
Sector:
Healthcare
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
6310 Nancy Ridge Drive
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001610618
ISIN: US1717571079
CUSIP: 171757107
